Q-omics provides the consensus-scored MICD profile across patient tissues and cancer cell-line models. MICD expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MICD is differentially expressed in 7, with the highest sampling consensus in CHOL. Additionally, MICD RNA expression shows 12,303 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight PAAD, CHOL, and LAML as cancer lineages where MICD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MICD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MICD survival associations across molecular data types. MICD RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MICD RNA expression–survival associations across cancer types. High MICD expression shows unfavorable associations in KIRP, ESCA, LIHC and KICH, but favorable associations in PAAD and HNSC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for MICD RNA expression.
This table summarizes MICD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for MICD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MICD shows lower tumor expression in COAD, BRCA and KICH and higher tumor expression in CHOL, STAD and LUAD. The CHOL box plot shows higher MICD RNA expression in tumor versus normal tissue (log2 FC = +0.216, t-test p = .018).
This table shows molecular features associated with MICD in patient tissues and cancer cell lines. In patient samples, MICD shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
